802 related articles for article (PubMed ID: 29299984)
21. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
22. Guselkumab for psoriasis: a critical appraisal of Phase III studies.
Yiu ZZ; Warren RB
Immunotherapy; 2018 Jan; 10(1):67-75. PubMed ID: 29043884
[TBL] [Abstract][Full Text] [Related]
23. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
Alunno A; Carubbi F; Cafaro G; Pucci G; Battista F; Bartoloni E; Giacomelli R; Schillaci G; Gerli R
Expert Opin Biol Ther; 2015; 15(12):1727-37. PubMed ID: 26653110
[TBL] [Abstract][Full Text] [Related]
24. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
Roman M; Chiu MW
Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
[TBL] [Abstract][Full Text] [Related]
25. Risankizumab (Skyrizi) for psoriasis.
Med Lett Drugs Ther; 2019 Jun; 61(1573):81-83. PubMed ID: 31170118
[No Abstract] [Full Text] [Related]
26. Emerging therapies in psoriasis: a systematic review.
Lee EB; Amin M; Bhutani T; Wu JJ
Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027
[TBL] [Abstract][Full Text] [Related]
27. IL-17 targeted therapies for psoriasis.
Chiricozzi A; Krueger JG
Expert Opin Investig Drugs; 2013 Aug; 22(8):993-1005. PubMed ID: 23731078
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
Mease PJ
Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
[TBL] [Abstract][Full Text] [Related]
29. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
30. Review of IL-17 inhibitors for psoriasis.
Amin M; Darji K; No DJ; Bhutani T; Wu JJ
J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
[No Abstract] [Full Text] [Related]
31. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.
Yamauchi PS; Bagel J
J Drugs Dermatol; 2015 Mar; 14(3):244-53. PubMed ID: 25738846
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
Fragoulis GE; Siebert S; McInnes IB
Annu Rev Med; 2016; 67():337-53. PubMed ID: 26565676
[TBL] [Abstract][Full Text] [Related]
33. A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.
Verstockt B; Deleenheer B; Van Assche G; Vermeire S; Ferrante M
Expert Opin Drug Saf; 2017 Jul; 16(7):809-821. PubMed ID: 28573876
[TBL] [Abstract][Full Text] [Related]
34. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
35. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.
Chen Y; Qian T; Zhang D; Yan H; Hao F
Immunotherapy; 2015; 7(9):1023-37. PubMed ID: 26055639
[TBL] [Abstract][Full Text] [Related]
37. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
38. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
[TBL] [Abstract][Full Text] [Related]
39. Anti IL-17 in psoriasis.
Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
[No Abstract] [Full Text] [Related]
40. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
Azevedo A; Torres T
Actas Dermosifiliogr; 2017 May; 108(4):305-314. PubMed ID: 27887675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
